Study design (if review, criteria of inclusion for studies)
Any randomized controlled trials comparing nontuberculous mycobacteria antibiotics to no antibiotic treatment, as well as one nontuberculous mycobacteria antibiotic regimen compared to another nontuberculous mycobacteria antibiotic regimen, in individuals with cystic fibrosis.
Adults and children diagnosed with CF who have NTM pulmonary infection (at least one respiratory specimen positive by culture for NTM)
antibiotics to treat NTM pulmonary infections. NTM antibiotics vs no antibiotic treatment as well as one NTM antibiotic regimen compared to another NTM antibiotic regimen. Single or multiple, oral, inhaled or intravenous antibiotics.
Primary outcomes: 1. Lung function (FEV1, FVC, FEF25â75); 2. Pulmonary exacerbations; 3. Adverse events.
One completed trial was identified by the searches, but data specific to individuals with cystic fibrosis could not be obtained from the pharmaceutical company.
This review did not find any evidence for the effectiveness of different antimicrobial treatment for nontuberculous mycobacteria lung disease in people with cystic fibrosis. Until such evidence becomes available, it is reasonable for clinicians to follow published clinical practice guidelines for the diagnosis and treatment of nodular or bronchiectatic pulmonary disease due to Mycobacterium avium complex or Mycobacterium abscessus in patients with cystic fibrosis.